Schizophrenia relapse prevention trail meets primary endpoint.

(From Business and Finance)

Schering-Plough has announced that its psychopharmacologic agent asenapine has met the primary endpoint in a longterm schizophrenia relapse prevention trial. Asenapine, which is administered as a fast dissolving sublingual tablet, is a psychopharmacologic compound with a unique human receptor signature.

The study was a randomised, placebo-controlled, doubleblind, multicentre, multinational clinical trial evaluating the efficacy and safety of sublingually administered asenapine compared to placebo in the prevention of relapse in subjects with schizophrenia.

A total of 700 subjects entered the open-label treatment with …